Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Practical Application of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) in Patients with Wounds.

Brem H, Howell R, Criscitelli T, Senderowicz A, Siegart N, Gorenstein S, Gillette B.

Surg Technol Int. 2018 Jun 1;32:61-66. Review.

PMID:
29611156
2.

A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma.

Voss MH, Hussain A, Vogelzang N, Lee JL, Keam B, Rha SY, Vaishampayan U, Harris WB, Richey S, Randall JM, Shaffer D, Cohn A, Crowell T, Li J, Senderowicz A, Stone E, Figlin R, Motzer RJ, Haas NB, Hutson T.

Ann Oncol. 2017 Nov 1;28(11):2754-2760. doi: 10.1093/annonc/mdx493.

PMID:
28950297
3.

Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial.

Keefe SM, Hoffman-Censits J, Cohen RB, Mamtani R, Heitjan D, Eliasof S, Nixon A, Turnbull B, Garmey EG, Gunnarsson O, Waliki M, Ciconte J, Jayaraman L, Senderowicz A, Tellez AB, Hennessy M, Piscitelli A, Vaughn D, Smith A, Haas NB.

Ann Oncol. 2016 Aug;27(8):1579-85. doi: 10.1093/annonc/mdw188. Epub 2016 Jun 8.

4.

A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms.

Figg WD, Monga M, Headlee D, Shah A, Chau CH, Peer C, Messman R, Elsayed YA, Murgo AJ, Melillo G, Ryan QC, Kalnitskiy M, Senderowicz AM, Hollingshead M, Arbuck SG, Sausville EA.

Cancer Chemother Pharmacol. 2014 Nov;74(5):955-67. doi: 10.1007/s00280-014-2569-7. Epub 2014 Sep 3.

5.

Similarities and differences in the oncology drug approval process between FDA and European Union with emphasis on in vitro companion diagnostics.

Senderowicz AM, Pfaff O.

Clin Cancer Res. 2014 Mar 15;20(6):1445-52. doi: 10.1158/1078-0432.CCR-13-1761.

6.

Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors.

Sausville E, Lorusso P, Carducci M, Carter J, Quinn MF, Malburg L, Azad N, Cosgrove D, Knight R, Barker P, Zabludoff S, Agbo F, Oakes P, Senderowicz A.

Cancer Chemother Pharmacol. 2014 Mar;73(3):539-49. doi: 10.1007/s00280-014-2380-5. Epub 2014 Jan 22.

7.

Information needed to conduct first-in-human oncology trials in the United States: a view from a former FDA medical reviewer.

Senderowicz AM.

Clin Cancer Res. 2010 Mar 15;16(6):1719-25. doi: 10.1158/1078-0432.CCR-09-2766. Epub 2010 Mar 9.

8.

Enhanced skin carcinogenesis and lack of thymus hyperplasia in transgenic mice expressing human cyclin D1b (CCND1b).

Rojas P, Benavides F, Blando J, Perez C, Cardenas K, Richie E, Knudsen ES, Johnson DG, Senderowicz AM, Rodriguez-Puebla ML, Conti CJ.

Mol Carcinog. 2009 Jun;48(6):508-16. doi: 10.1002/mc.20489.

9.

CDK2 activation in mouse epidermis induces keratinocyte proliferation but does not affect skin tumor development.

Macias E, Miliani de Marval PL, De Siervi A, Conti CJ, Senderowicz AM, Rodriguez-Puebla ML.

Am J Pathol. 2008 Aug;173(2):526-35. doi: 10.2353/ajpath.2008.071124. Epub 2008 Jul 3.

10.

Erlotinib/gemcitabine for first-line treatment of locally advanced or metastatic adenocarcinoma of the pancreas.

Senderowicz AM, Johnson JR, Sridhara R, Zimmerman P, Justice R, Pazdur R.

Oncology (Williston Park). 2007 Dec;21(14):1696-706; discussion 1706-9, 1712, 1715.

11.

Expression of CDK4 or CDK2 in mouse oral cavity is retained in adult pituitary with distinct effects on tumorigenesis.

Macias E, Miliani de Marval PL, Senderowicz A, Cullen J, Rodriguez-Puebla ML.

Cancer Res. 2008 Jan 1;68(1):162-71. doi: 10.1158/0008-5472.CAN-07-2461.

12.

S-Phase-specific activation of PKC alpha induces senescence in non-small cell lung cancer cells.

Oliva JL, Caino MC, Senderowicz AM, Kazanietz MG.

J Biol Chem. 2008 Feb 29;283(9):5466-76. Epub 2007 Dec 26.

13.

Inhibitors of cyclin-dependent kinase modulators for cancer therapy.

Senderowicz AM.

Prog Drug Res. 2005;63:183-206. Review.

PMID:
16265881
14.
15.
16.

Role of cell cycle control and cyclin-dependent kinases in breast cancer.

Senderowicz AM.

Breast Dis. 2002;15:33-52. No abstract available.

PMID:
15687644
17.

Targeting cell cycle and apoptosis for the treatment of human malignancies.

Senderowicz AM.

Curr Opin Cell Biol. 2004 Dec;16(6):670-8. Review.

PMID:
15530779
18.

Effects of alpha1-acid glycoprotein on the clinical pharmacokinetics of 7-hydroxystaurosporine.

Sparreboom A, Chen H, Acharya MR, Senderowicz AM, Messmann RA, Kuwabara T, Venzon DJ, Murgo AJ, Headlee D, Sausville EA, Figg WD.

Clin Cancer Res. 2004 Oct 15;10(20):6840-6.

19.

Assays for cyclin-dependent kinase inhibitors.

Senderowicz AM.

Methods Mol Biol. 2004;285:69-78. No abstract available.

PMID:
15269400
21.

Metabolism of UCN-01 in isolated perfused rat liver: role of Mrp2 in the biliary excretion of glucuronides.

Hagenauer B, Maier-Salamon A, Thalhammer T, Zöllner P, Senderowicz A, Jäger W.

Oncol Rep. 2004 May;11(5):1069-75.

PMID:
15069549
22.
23.
24.

The role of hepatic Mrp2 in the interaction of flavopiridol and bilirubin: impact on therapy.

Jäger W, Gehring E, Hagenauer B, Aust S, Senderowicz A, Thalhammer T.

Int J Clin Pharmacol Ther. 2003 Dec;41(12):610-1. No abstract available.

PMID:
14692715
25.

Cell cycle modulators for the treatment of lung malignancies.

Senderowicz AM.

Clin Lung Cancer. 2003 Nov;5(3):158-68. Review.

PMID:
14667271
26.

Small-molecule cyclin-dependent kinase modulators.

Senderowicz AM.

Oncogene. 2003 Sep 29;22(42):6609-20. Review.

PMID:
14528286
27.

Clinical pharmacology of flavopiridol following a 72-hour continuous infusion.

Rudek MA, Bauer KS Jr, Lush RM 3rd, Stinson SF, Senderowicz AM, Headlee DJ, Arbuck SG, Cox MC, Murgo AJ, Sausville EA, Figg WD.

Ann Pharmacother. 2003 Oct;37(10):1369-74.

PMID:
14519054
28.

Biliary excretion of flavopiridol and its glucuronides in the isolated perfused rat liver: role of multidrug resistance protein 2 (Mrp2).

Jäger W, Gehring E, Hagenauer B, Aust S, Senderowicz A, Thalhammer T.

Life Sci. 2003 Oct 17;73(22):2841-54.

PMID:
14511769
29.

Novel small molecule cyclin-dependent kinases modulators in human clinical trials.

Senderowicz AM.

Cancer Biol Ther. 2003 Jul-Aug;2(4 Suppl 1):S84-95. Review.

PMID:
14508085
30.

Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.

Senderowicz AM.

Cancer Chemother Pharmacol. 2003 Jul;52 Suppl 1:S61-73. Epub 2003 Jun 18. Review.

PMID:
12819936
31.

Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation.

Solomon DA, Wang Y, Fox SR, Lambeck TC, Giesting S, Lan Z, Senderowicz AM, Conti CJ, Knudsen ES.

J Biol Chem. 2003 Aug 8;278(32):30339-47. Epub 2003 May 12. Erratum in: J Biol Chem. 2004 Jul 16;279(29):30914.

32.

Assays for cyclin-dependent kinase inhibitors.

Senderowicz AM, Lahusen T.

Methods Mol Med. 2003;85:39-48. Review. No abstract available.

PMID:
12710195
33.

Cyclin-dependent kinases as targets for cancer therapy.

Senderowicz AM.

Cancer Chemother Biol Response Modif. 2002;20:169-96. Review.

PMID:
12703205
34.
35.

Flavopiridol-related proinflammatory syndrome is associated with induction of interleukin-6.

Messmann RA, Ullmann CD, Lahusen T, Kalehua A, Wasfy J, Melillo G, Ding I, Headlee D, Figg WD, Sausville EA, Senderowicz AM.

Clin Cancer Res. 2003 Feb;9(2):562-70.

36.

Clinical pharmacology and pharmacogenetics of flavopiridol 1-h i.v. infusion in patients with refractory neoplasms.

Zhai S, Sausville EA, Senderowicz AM, Ando Y, Headlee D, Messmann RA, Arbuck S, Murgo AJ, Melillo G, Fuse E, Figg WD.

Anticancer Drugs. 2003 Feb;14(2):125-35.

PMID:
12569299
37.

Cyclin-dependent kinases as new targets for the prevention and treatment of cancer.

Senderowicz AM.

Hematol Oncol Clin North Am. 2002 Oct;16(5):1229-53. Review.

PMID:
12512390
38.

Antitumor activity of UCN-01 in carcinomas of the head and neck is associated with altered expression of cyclin D3 and p27(KIP1).

Patel V, Lahusen T, Leethanakul C, Igishi T, Kremer M, Quintanilla-Martinez L, Ensley JF, Sausville EA, Gutkind JS, Senderowicz AM.

Clin Cancer Res. 2002 Nov;8(11):3549-60.

39.

Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms.

Tan AR, Headlee D, Messmann R, Sausville EA, Arbuck SG, Murgo AJ, Melillo G, Zhai S, Figg WD, Swain SM, Senderowicz AM.

J Clin Oncol. 2002 Oct 1;20(19):4074-82.

PMID:
12351605
41.

Second symposium of novel molecular targets for cancer therapy.

Frijhoff AF, Conti CJ, Senderowicz AM.

Oncologist. 2002;7 Suppl 3:1-3. No abstract available.

42.

Flavopiridol, a novel cyclin-dependent kinase inhibitor, in clinical development.

Zhai S, Senderowicz AM, Sausville EA, Figg WD.

Ann Pharmacother. 2002 May;36(5):905-11. Review.

PMID:
11978170
44.

Cyclin-dependent kinase modulators: a novel class of cell cycle regulators for cancer therapy.

Senderowicz AM.

Cancer Chemother Biol Response Modif. 2001;19:165-88. Review.

PMID:
11686013
45.

Small molecule modulators of cyclin-dependent kinases for cancer therapy.

Senderowicz AM.

Oncogene. 2000 Dec 27;19(56):6600-6. Review.

46.

Characterization of autoantibodies against uridine-diphosphate glucuronosyltransferase in patients with inflammatory liver diseases.

Bachrich T, Thalhammer T, Jäger W, Haslmayer P, Alihodzic B, Bakos S, Hitchman E, Senderowicz AM, Penner E.

Hepatology. 2001 May;33(5):1053-9.

PMID:
11343231
47.

First symposium of novel molecular targets for cancer therapy.

Politi PM, Senderowicz AM.

Oncologist. 2001;6(2):207-12. No abstract available.

48.

Phase I trial of 72-hour continuous infusion UCN-01 in patients with refractory neoplasms.

Sausville EA, Arbuck SG, Messmann R, Headlee D, Bauer KS, Lush RM, Murgo A, Figg WD, Lahusen T, Jaken S, Jing X, Roberge M, Fuse E, Kuwabara T, Senderowicz AM.

J Clin Oncol. 2001 Apr 15;19(8):2319-33.

PMID:
11304786
49.

Histone acetylation and the cell-cycle in cancer.

Wang C, Fu M, Mani S, Wadler S, Senderowicz AM, Pestell RG.

Front Biosci. 2001 Apr 1;6:D610-29. Review.

PMID:
11282573
50.

In vitro glucuronidation of the cyclin-dependent kinase inhibitor flavopiridol by rat and human liver microsomes: involvement of UDP-glucuronosyltransferases 1A1 and 1A9.

Hagenauer B, Salamon A, Thalhammer T, Kunert O, Haslinger E, Klingler P, Senderowicz AM, Sausville EA, Jäger W.

Drug Metab Dispos. 2001 Apr;29(4 Pt 1):407-14.

PMID:
11259324

Supplemental Content

Loading ...
Support Center